This systematic literature reviewdescribes adverse events (AEs) among patients with soft tissue sarcoma (STS)who received secondline\nor later anticancer therapies. Searches were conducted in PubMed, EMBASE, and Cochrane Central Register of Controlled\nTrials for studies of adults with advanced or metastatic STS who received systemic anticancer therapy before enrollment in a\nrandomized-controlled trial of pazopanib, another targeted cancer agent, or cytotoxic chemotherapy.Of 204 publications identified,\nseven articles representing six unique studies met inclusion criteria. Additional safety results for pazopanib were identified\non ClinicalTrials.gov. Hematologic toxicities were common with all therapies evaluated (pazopanib, trabectedin, dacarbazine �±\ngemcitabine, gemcitabine �± docetaxel, cyclophosphamide, and ifosfamide). Studies differed in AE type, timing of assessment, and\noutcomes reported, although patient populations and AE assessment timing were relatively similar for pazopanib and trabectedin.\nAEs that were more common with trabectedin than pazopanib were anemia, neutropenia, nausea/vomiting, and elevations in\naspartate aminotransferase and alanine aminotransferase. An AE that was more common with pazopanib than trabectedin was\nanorexia. Only the pazopanib study reported AE frequencies versus placebo. A planned meta-analysis was not feasible, as there\nwas no common comparator. More well-designed studies that include common comparators are needed for comparison of safety\neffects among treatments for STS.
Loading....